Semnur Pharmaceuticals, Inc.
SMNR
$0.84
$0.045.01%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 592.47% | 906.28% | 14,120.75% | -37.95% | -16.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 588.12% | 693.56% | 11,656.09% | -10.00% | -55.84% |
| Operating Income | -588.12% | -693.56% | -11,656.09% | 10.00% | 55.84% |
| Income Before Tax | -588.12% | -693.56% | -11,656.09% | 10.00% | 55.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -588.12% | -693.56% | -11,656.09% | 10.00% | 55.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -588.12% | -693.56% | -11,656.09% | 10.00% | 55.84% |
| EBIT | -588.12% | -693.56% | -11,656.09% | 10.00% | 55.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -503.03% | -625.64% | -11,540.00% | 10.14% | 64.89% |
| Normalized Basic EPS | -490.48% | -637.50% | -11,434.15% | 9.30% | 64.41% |
| EPS Diluted | -503.03% | -625.64% | -11,540.00% | 10.14% | 64.89% |
| Normalized Diluted EPS | -490.48% | -637.50% | -11,434.15% | 9.30% | 64.41% |
| Average Basic Shares Outstanding | 15.10% | 8.72% | 0.84% | 0.00% | 25.00% |
| Average Diluted Shares Outstanding | 15.10% | 8.72% | 0.84% | 0.00% | 25.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |